Effective partnering and ASIA market assessment platform – ACCESS ASIA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Asia market. ACCESS ASIA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.
Who should present?
Global pharma/biotech companies:
- Looking for out-licensing opportunities in Asia
- With clinical-stage assets
- Focusing on Oncology, CNS, Cardiovascular, Ophthalmology, Orthopedics, Pediatrics, and GI areas
- Looking for equity investment opportunities in China (Chinese companies only)
Who are the attendees?
- 40% are Chinese pharma/biotechs looking for in-licensing opportunities to enrich pipeline
- 35% are Pharma/biotechs outside China looking for in-licensing opportunities to enrich pipeline in China and other regions
- 20% are VCs and PEs looking for pharma/biotech investment opportunities in China
Why China ?
In/out-licensing is becoming the major business strategy among Chinese pharma.
China’s out-licensing market is rebounding. Average upfronts rose from $56M in 2022 to $115M in 2025, with the NewCo model accelerating—12 deals signed in 2025 compared to 6 in 2024—adding equity upside. In-licensing also recovered 66% from a low base, as MNCs re-engage through CSO and co-commercialization strategies amid anti-corruption and VBP pricing pressures.
Why ACCESS ASIA?
Broad Chinese Strategic Partners Coverage
Compared to other conferences such as Bio Convention or Bio Showcase, ACCESS ASIA has the broadest coverage of Asia strategic partners and investors who are looking for in/out licensing opportunities.
Easy China Market Assessment
We gather interests for presenting companies within two weeks after the presentations, an easy and effective way to assess the level of interest in the Asia market.
More Exposure via Different Channels
ACCESS ASIA promotes presenting companies through various channels in deluding asset listing on platform, video roadshow on live day and on demand, asset report distribution to our members, and promoting to targeted investors through email and social media.
Upcoming Events
As the BIO Convention approaches, ACCESS ASIA and YAFO Capital will host the ACCESS ASIA Networking Reception @ BIO 2026 in San Diego, bringing together professionals across pharma, biotech, and investment who are engaged in Asia–global partnerships.
Set ahead of the main conference days, this evening reception offers a relaxed setting to connect with peers active in China and broader Asia, meet potential partners and investors, and start meaningful conversations before the week accelerates.
The reception is designed for biotech, pharma, investment funds, and senior decision-makers focused on cross-border biotech partnerships.
Past Events
ACCESS ASIA is a series of events including ACCESS ASIA Spring BD Salon in Shanghai, East Meets West Mixing Dinner @ JPM, ACCESS ASIA BD Forum @ BIO International Convention, CHINA BD Forum (September each year), and ACCESS ASIA Online Partnering.
BioToChina.org 